Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenerative Medical Technology (RMTG) Return on Sales (2018 - 2025)

Historic Return on Sales for Regenerative Medical Technology (RMTG) over the last 8 years, with Q3 2025 value amounting to 3.33%.

  • Regenerative Medical Technology's Return on Sales fell 24400.0% to 3.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.32%, marking a year-over-year increase of 7600.0%. This contributed to the annual value of 1.35% for FY2024, which is 16400.0% up from last year.
  • Per Regenerative Medical Technology's latest filing, its Return on Sales stood at 3.33% for Q3 2025, which was down 24400.0% from 1.33% recorded in Q2 2025.
  • Regenerative Medical Technology's 5-year Return on Sales high stood at 0.12% for Q4 2022, and its period low was 106.3% during Q1 2021.
  • For the 5-year period, Regenerative Medical Technology's Return on Sales averaged around 12.36%, with its median value being 1.33% (2025).
  • The largest annual percentage gain for Regenerative Medical Technology's Return on Sales in the last 5 years was 10519500bps (2021), contrasted with its biggest fall of -606600bps (2021).
  • Quarter analysis of 5 years shows Regenerative Medical Technology's Return on Sales stood at 6.18% in 2021, then skyrocketed by 102bps to 0.12% in 2022, then tumbled by -2469bps to 2.87% in 2023, then skyrocketed by 85bps to 0.42% in 2024, then plummeted by -688bps to 3.33% in 2025.
  • Its Return on Sales was 3.33% in Q3 2025, compared to 1.33% in Q2 2025 and 0.56% in Q1 2025.